Bedaquiline fumarate
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: ; Chetan Lokhande, M.B.B.S [2]
Overview
Bedaquiline (trade name Sirturo, code names TMC207 and R207910) is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica.[1] It is the first new medicine to fight TB in more than forty years,[2][3] and is specifically approved to treat multi-drug-resistant tuberculosis.
Category
Antimycobacterial
US Brand Names
Sirturo®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Other Size Packages Available | Labels and Packages
Mechanisms of Action
Bedaquiline affects the proton pump for ATP synthase. This mechanism is unlike that of the quinolones, whose target is DNA gyrase.[4]
References
- ↑ de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K (2007). "A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910". Proteins. 67 (4): 971–80. doi:10.1002/prot.21376. PMID 17387738. Unknown parameter
|month=ignored (help) - ↑ "FDA Approves 1st New Tuberculosis Drug in 40 Years". ABC News. Retrieved 31 December 2012.
- ↑ "F.D.A. Approves New Tuberculosis Drug". New York Times. Retrieved 31 December 2012.
- ↑ Kotz J (2005). "Targeting tuberculosis". Nature Chemical Biology. doi:10.1038/nchembio002. Unknown parameter
|month=ignored (help)